US FDA advisors back AstraZeneca's Crestor for CV disease prevention
This article was originally published in Scrip
Executive Summary
The US FDA's outside experts have overwhelmingly endorsed the use of AstraZeneca's Crestor (rosuvastatin) for primary prevention of cardiovascular disease based on the results of the JUPITER trial, clearing the way for a significant broadening of the statin's indication.